News
GSK’s Hibsago Approved in the US for Chronic Hepatitis B
GSK’s Hibsago is the first FDA-approved antisense oligonucleotide (ASO) for treating chronic hepatitis B.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
GSK’s Hibsago is the first FDA-approved antisense oligonucleotide (ASO) for treating chronic hepatitis B.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
